



RECEIVED
AUG 13 2001
THE UNITED STATES PATENT AND TRADEMARK OFFICE
TECH CENTER 1600/2900

In re Application of :

BUCHHOLZ, Herwig, et al.

Serial No. : 09/830,288

Filed : 25 April 2001

Title: COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF
CARDIOVASCULAR DISEASES

JAC
Apperson
8/15/01

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.

Copies of materials listed but not attached were cited in parent application Serial No. _____

Copies of materials listed but not attached were cited in an International Search Report dated 26 April 2000; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed 05 June 2001.

Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.

Also included are the pending U.S. applications listed below, copies of which are attached:

FEES

No fee is required for this Information Disclosure Statement because:

This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;

This Information Disclosure Statement is being filed before the mailing of a first action on the merits;

This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.

A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a

notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).

A check is attached: This Information Disclosure Statement is being filed after the mailing date of a notice of allowance under § 1.311 but before the payment of the issue fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.

CERTIFICATION


Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If appropriate, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Jennifer Branigan
Registration No.40,921
Patent Agent

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: 8 August 2001
Jjb:K:\Merck\1943\Information Disclosure Statement.doc